Gout and Cardiovascular Risk: Why Recurrent Gout Should Be Taken Seriously

1 Jun

Black and white clinical image illustrating discussion of gout, uric acid and cardiovascular risk during a rheumatology consultation.

One of the patients who came to see me had been having repeated gout attacks for some time. The flares were painful, disruptive and increasingly hard to dismiss as “just one of those things”. He already knew his cholesterol was raised and was taking a statin, but his gout had largely been treated as a series of isolated attacks rather than as part of a broader long-term health picture. Once we focused on bringing his uric acid down properly with allopurinol, the recurrent attacks stopped.

Just as importantly, the consultation became an opportunity to take the condition more seriously overall — not simply by treating flares, but by looking properly at gout, urate levels and the wider cardiovascular and metabolic context. That is the part of gout that is often underestimated. NICE guidance specifically recommends explaining the link between gout and cardiovascular risk factors or comorbidities, and assessing and managing those risks as part of gout care.

Many people still think of gout as a painful but fairly simple joint problem — often caricatured as something caused by rich food and excess alcohol. There is some truth in the idea that lifestyle can influence gout, but the reality is much more complex. Gout is an inflammatory arthritis driven by urate crystal deposition, and it commonly sits alongside broader cardiometabolic problems such as hypertension, obesity, chronic kidney disease, diabetes and dyslipidaemia. NICE’s gout guideline explicitly tells clinicians to discuss cardiovascular risk factors and comorbidities including hypertension, diabetes, obesity, chronic kidney disease, smoking and hyperlipidaemia.

Why gout should not be treated as “just a flare”

Hyperuricaemia — a raised uric acid level — is the most important risk factor for developing gout, and the level of urate correlates with gout risk. But once a patient has gout, the question should not be limited to “how do we stop this attack?” Recurrent flares, tophi, joint damage and chronic symptoms are reasons to think long term, and NICE recommends urate-lowering therapy for people with multiple flares, tophi, chronic gouty arthritis, erosive disease, certain comorbidities, or very high serum urate.

That matters because repeated attacks usually mean the underlying urate problem has not been dealt with properly. A short course of colchicine, an NSAID or steroids may help a flare settle, but they do not address the reason the flares keep happening. This is one reason gout deserves more respect than it often gets. It is a chronic condition with acute manifestations, not simply a series of unrelated painful episodes. NICE’s guideline is built around treat-to-target urate lowering rather than flare-only treatment.

What is the link between gout and cardiovascular risk?

This is where the discussion becomes especially important. Gout and hyperuricaemia are associated with increased cardiovascular risk. NICE CKS states that hyperuricaemia is associated with increased risk of cardiovascular disease and cardiovascular mortality, and highlights links with coronary heart disease, heart failure, stroke and peripheral arterial disease. A 2024 Oxford-led population study also reported that people with gout had a higher overall risk of cardiovascular disease than those without gout.

That does not mean that every person with gout will go on to develop heart disease, nor does it mean that gout is the sole cause. Part of the reason for the association is that gout often clusters with other risk factors that already increase cardiovascular risk, such as obesity, hypertension, diabetes and kidney disease. But from a practical clinical perspective, the key message is the same: recurrent gout should prompt broader assessment, not just repeated flare treatment. That is exactly the approach NICE recommends.

Does high urate itself matter?

Yes, but again the answer needs nuance. High urate clearly matters for gout, because it is the biochemical setting in which monosodium urate crystals form. NICE CKS describes hyperuricaemia as the most important risk factor for gout, and notes that the risk of disease rises as urate rises. There is also a substantial literature linking raised urate to adverse cardiovascular outcomes, but the relationship is biologically and clinically complicated because urate is entangled with many other metabolic and vascular risk factors.

So the most defensible way to explain this to patients is not “high urate means heart disease”, but rather: high urate and gout often sit within a wider risk profile that deserves proper attention. That is a more accurate and more useful clinical message.

What does proper long-term management involve?

In gout, proper long-term management usually means more than simply reacting to attacks. It means making sure the diagnosis is secure, measuring and tracking serum urate, deciding whether urate-lowering therapy is indicated, and treating to target. NICE recommends starting allopurinol at a low dose and titrating upwards, with a target serum urate below 360 micromol/L, and below 300 micromol/L for people with tophi, chronic gouty arthritis or ongoing frequent flares.

This is where allopurinol can make a major practical difference. In the right patient, it reduces urate and can prevent recurrent flares when titrated properly and continued. NICE also specifically recommends allopurinol as first-line treatment for people with gout who have major cardiovascular disease. That is an important and very patient-relevant point.

Does allopurinol improve cardiovascular prognosis?

This is the point that needs to be handled carefully. It is entirely legitimate to say that controlling urate with allopurinol can be very effective at preventing recurrent gout attacks. It is also legitimate to say that treating gout properly should form part of better long-term health management. But it would be too strong to say that allopurinol has been definitively proven to improve cardiovascular outcomes directly. The large ALL-HEART trial found that allopurinol did not improve major cardiovascular outcomes in patients with ischaemic heart disease compared with usual care, and later summaries of that trial have reinforced the same conclusion.

So the most credible message is this: allopurinol is very important for gout control, and gout should prompt broader cardiovascular risk attention, but the evidence does not currently justify promising that allopurinol itself will reduce future heart attacks or strokes. That distinction matters, and it makes the advice more trustworthy rather than less.

What else should be checked in someone with gout?

This is one of the reasons a proper gout review can be useful. A patient with recurrent gout should not just be asked how often the attacks happen. It is also sensible to look at blood pressure, lipids, diabetes risk, kidney function, body weight, alcohol, smoking, medications and the general metabolic picture. The British Society for Rheumatology guidance and NICE-aligned primary care materials both support routine cardiovascular risk-factor screening in gout.

This is also where specialist input can be helpful. Some patients have straightforward gout that responds well to primary-care management. Others have recurrent flares despite treatment, uncertainty over diagnosis, renal impairment, major comorbidity, difficulty reaching target urate, or a broader inflammatory picture. In those cases, a more detailed review may help clarify what is driving the attacks, whether the urate target is being reached, and whether the overall long-term plan is robust enough.

The bottom line

Gout should not be treated as nothing more than an occasional painful flare. Recurrent gout usually means there is an underlying urate problem that needs proper long-term management, and it should also prompt attention to wider cardiovascular and metabolic risk. NICE guidance is clear that gout care should include discussion and management of cardiovascular risk factors and comorbidities, and that allopurinol is first-line urate-lowering therapy, including in patients with major cardiovascular disease.

So the important message for patients is this: getting gout under control matters not only because it prevents recurrent attacks, but because recurrent gout is often a sign that the wider health picture deserves to be taken seriously too. That does not mean every patient with gout is heading for heart disease, and it does not mean allopurinol has been proven to improve cardiovascular outcomes directly. It does mean that recurrent gout deserves more than flare treatment alone.